ISSN 1948-5875
70 papers in the library · 141 citations · publishing 2020-2026
ACS Medicinal Chemistry Letters June 10, 2025 Ram W. Sabnis
Provided herein are novel indazole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters May 8, 2025 Robert B. Kargbo 1 citation
DMT induces rapid antidepressant effects, but acute sympathomimetic side effects, particularly hypertension and tachycardia, limit its use. This study describes coformulations with short-acting beta-blockers or nitrates, matched to DMT's pharmacokinetics, to mitigate peripheral cardiovascular risks without compromising central therapeutic action, facilitating safer psychedelic therapy in...
ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo
Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for depression, PTSD, and addiction. Relaxing neural filters reveal altered states of consciousness, challenging perceptions of reality. This Viewpoint explores their neurobiological mechanisms and AI's role in augmenting psychiatric treatments.
ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo
Psilocybin demonstrates a clinically meaningful reduction in phantom and residual limb pain. Adaptive sensory environments (ASEs) separately offer biosensor-guided modulation of psychological states during psychoactive therapy. This Patent Highlight explores the pharmacological findings of a psilocybin trial and discusses future integration with ASE systems to precision and scale...
ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo
Recent advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms mark a new frontier in precision medicine. These innovations address critical challenges in neurological and psychiatric disorders, chronic pain management, and computational accessibility. By harnessing the principles of receptor modulation, targeted...
ACS Medicinal Chemistry Letters March 13, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel compounds as 5-HT2A receptor modulators, pharmaceutical compositions, use of such compounds in treating psychiatric and neurological disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters March 11, 2025 Robert B. Kargbo
Emerging innovations across psychedelics, artificial intelligence (AI), and communication technologies are reshaping healthcare and beyond. This Patent Highlight showcases advancement in sublingual delivery systems for psychedelics, asymmetric phenylethylamine compounds, AI-assisted communication positioning, and multi-modal data fusion, respectively. These inventions address challenges like...
ACS Medicinal Chemistry Letters February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
High Resolution Image Download MS PowerPoint Slide Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters February 13, 2025 Robert B. Kargbo
Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors...
ACS Medicinal Chemistry Letters February 11, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental illness or CNS disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
Provided herein are novel indoline derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 23, 2025 Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel pyrrolopyridine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental illnesses, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 23, 2025 Robert B. Kargbo
The intersection of artificial intelligence (AI), digital therapeutics, and advanced communication frameworks offers transformative opportunities for addressing mental health disorders, neurodegenerative diseases, and communication challenges in modern networks. This Patent Highlight examines three pivotal patents that introduce deuterated empathogens for safer psychiatric treatments,...
ACS Medicinal Chemistry Letters January 9, 2025 Ram W. Sabnis 7 citations
Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.
ACS Medicinal Chemistry Letters January 9, 2025 Robert B. Kargbo
Artificial intelligence (AI) offers transformative potential in psychedelic research by addressing limitations in personalized treatment, predicting therapeutic outcomes, and understanding complex biological and environmental factors. AI-driven models provide new insights into long-term efficacy, set and setting optimization, and alternative treatment methods, advancing psychedelic therapy into...
ACS Medicinal Chemistry Letters January 4, 2025 Ram W. Sabnis
Provided herein are novel 3-cycloaminoindole compounds as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
ACS Medicinal Chemistry Letters December 12, 2024 Robert B. Kargbo
Psychedelic compounds, particularly psilocybin and psilocin, have shown significant therapeutic potential in treating neurological and psychiatric disorders. However, their bioavailability, rapid metabolism, and stability challenges have limited their clinical use. This Patent Highlight reviews recent innovations in psychedelic drug delivery systems and the development of psilocin analogs aimed...
ACS Medicinal Chemistry Letters November 14, 2024 Robert B. Kargbo 3 citations
Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in treating various mental health disorders. This Patent Highlight evaluates findings from multiple recent patents that explore novel applications of these compounds, including their use in severe psychiatric conditions such as depression, anxiety, and...
ACS Medicinal Chemistry Letters November 11, 2024 Robert B. Kargbo
High Resolution Image Download MS PowerPoint Slide Recent innovations in psychedelic research have led to the development of novel compounds designed to enhance the therapeutic potential of psilocin and related tryptamines. This Patent Highlight reviews three essential patents that focus on improving the stability, bioavailability, and efficacy of these compounds for treating mental health...
ACS Medicinal Chemistry Letters October 15, 2024 Robert B. Kargbo 1 citation
Psilocybin, a naturally occurring psychedelic compound, has recently emerged as a promising therapeutic agent for mental health. This Patent Highlight explores the innovative approaches to harnessing psilocybin's potential across various contexts. These include clinical trials targeting severe psychiatric conditions, the integration of low-dose psilocybin into dietary products to promote...
ACS Medicinal Chemistry Letters August 21, 2024 Robert B. Kargbo
Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therapeutic agents in mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. This Patent Highlight integrates findings from three patent applications, each contributing unique insights into the...
ACS Medicinal Chemistry Letters August 21, 2024 Robert B. Kargbo
This article explores groundbreaking advancements in psychedelic research, highlighting the development of novel lysergic acid derivatives with modified LSD-like actions and innovative dosing methods based on ABCF1 gene expression for psilocybin. It also examines new strategies for treating binge eating disorder using psychedelics and techniques for neuroenhancement to enhance emotional...
ACS Medicinal Chemistry Letters August 8, 2024 Robert B. Kargbo 1 citation
Ketamine, originally developed as an anesthetic, has shown significant potential for treating depression, chronic pain, and other conditions. However, its conventional formulations often result in side effects such as hallucinations and dizziness due to rapid spikes in blood concentration. This article explores recent patents that optimize ketamine delivery and efficacy: subcutaneous injectable...
ACS Medicinal Chemistry Letters May 8, 2024 Robert B. Kargbo 2 citations
This Patent Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highlights the development of transdermal formulations for psychoactive alkaloids, neuroenhancement techniques to augment emotional responses, and the intravenous infusion of psilocybin or psilocin for various therapeutic purposes. Additionally, it delves...
ACS Medicinal Chemistry Letters March 14, 2024 Robert B. Kargbo
This Patent Highlight explores ground-breaking advancements in neurostimulation, psychedelic therapy, and brain function optimization from recent innovations. It examines methods for altering brain states through AI-driven non-invasive neurostimulation, potentially contributing to personalized brain therapy. The publication also delves into the therapeutic potential of N-isopropyl tryptamines...